We are pleased to share that our portfolio company, Trogenix, today unveils its revolutionary precision viral immunotherapy platform, Odysseus, aimed at transforming cancer treatment. https://lnkd.in/ec64Q3Vm Their lead programme targets the most aggressive form of brain cancer, glioblastoma (GBM), in a precise manner. Odysseus utilises a Synthetic Super-Enhancer (SSE) technology enabling highly selective and potent gene control to distinguish cancer cells in situ, without the reliance on surface antigens. Trogenix have produced curative responses whilst evading toxicity and persistent anti-tumour immunity via their unique ‘Trojan Horse’ approach. #4BIO #Trogenix #Biotech #PrecisionTherapy #Innovation
4BIO Capital
Venture Capital and Private Equity Principals
London, England 4,925 followers
London-based venture fund investing in advanced therapies
About us
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com
- Website
-
http://www.4biocapital.com
External link for 4BIO Capital
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Biotech, Venture Capital, Private Equity, and Non-discretionary advice
Locations
-
Primary
Get directions
78 Pall Mall
London, England, GB
Employees at 4BIO Capital
Updates
-
We are pleased to become the first UK Venture Fund Certified under the Japan Agency for Medical Research and Development (AMED)’s “Drug Discovery Venture Ecosystem Strengthening Project”. https://lnkd.in/emmT5TPT This allows us to support life science projects relevant to the Japanese ecosystem and healthcare needs through AMED’s non-dilutive funding model. Ventures backed by AMED-certified VCs can apply for AMED grants, receiving up to twice the investment amount as grant funding without dilution. This accreditation validates our commitment to advancing drug discovery and development in Japan and we look forward to further supporting innovative biotech ventures and contributing to the growth of Japan's life sciences ecosystem. #AMED #Japan #Biotech #Innovation #VentureCapital #GeneTherapy #AdvancedTherapies
-
-
Congratulations to our portfolio company Ascend Advanced Therapies! Ascend is partnering with EW Healthcare Partners to expand its US footprint and capabilities and to continue investing further in infrastructure. Additionally, EW portfolio company, Advanced BioScience Laboratories (ABL), will become part of Ascend. This transformative deal brings together complementary services of both companies, further strengthening Ascend’s service offering to its customers. This strategic merger follows Ascend's recent expansion in Florida and Germany earlier in the year, demonstrating the rapid execution of its growth strategy. Congratulations to Fred Cohen, Mike Stella, and the entire Ascend team! We look forward to supporting the next phase of growth alongside EW Healthcare Partners. #4BIO #VentureCapital #Biotech #GeneTherapy #AdvancedTherapies
We continue growing and evolving. Today, we are thrilled to align with ABL to deepen our commitment to being an exceptional advanced #therapies #partner. The addition of the ABL Rockville team and facility aligns more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated virus (AAV) production. The merger also expands fill/finish capacity in the US making the combined group one of the few suppliers with a comprehensive R&D to commercial offering in the market. https://lnkd.in/eAYwrgds
-
-
Owen Smith, Partner, sat down with Megan Thomas from Drug Discovery World to discuss 4BIO’s investment strategies and future trends in cell and gene therapy: https://lnkd.in/eaSTRWnh Key topics discussed include: ✅The promise of AAV gene therapies in non-renewing tissues and cell therapies in haematology ✅The challenges that the cell and gene therapy sector is experiencing and working to overcome ✅Regulatory and reimbursement complexities, especially in the EU #4BIO #Interview #Podcast #VC #AdvancedTherapies
-
-
We are excited to announce the appointment of Therese Liechtenstein as an Investment Director and Tay Salimullah as a Venture Partner! https://lnkd.in/erbGhKxN Thera has significant experience in leading company creations and investments in therapeutics companies and will be crucial in contributing towards advancing transformative medicines at 4BIO. Tay has over 20 years of leadership experience in rare disease pharma and a proven track record of commercialising high-value technologies, including cell and gene therapies, and brings invaluable insight to drive success for us and our portfolio companies. Welcome both! #4BIO #NewHire #Appointment #VC #AdvancedTherapies
-
-
We are delighted to share that our portfolio company, Vianautis, has entered a collaboration agreement with Eli Lilly and Company. This partnership will develop further ViaNautis’ PolyNaut® platform, a versatile nanomedicine technology directing intracellular delivery of therapeutic modalities, assisted by GOTO® technology. #4BIO #ViaNautis #Lilly #Biotech #collaboration #polyNaut
Today we have announced a strategic collaboration with Eli Lilly and Company to develop novel genetic medicines using our polyNaut® platform: https://lnkd.in/eH7Qh53F This marks a significant step forward in leveraging our polyNaut® nanovesicle platform, designed to precisely target specific tissues and cell types, even in hard-to-reach areas such as the central nervous system. With its ability to efficiently deliver genetic cargoes, polyNaut® has the potential to transform genetic nanomedicine delivery and address significant unmet needs. #ViaNautis #polyNaut #Lilly #Biotech #Nanomedicine
-
We are excited to share that we have led a $28.4 million Series A Financing round of March Biosciences: https://lnkd.in/gGf-EXH3 This fundraise will allow March Bio to further develop its rapidly progressing CAR-T therapy, MB-105, for the treatment of relapsed and refractory CD5+ T-cell Lymphoma. The candidate drug has shown promising Phase 1 results, and the proceeds from 4BIO will support the transition to Phase 2 clinical trials in early 2025. #4BIO #VC #MarchBio #Biotech #Fundraise
-
-
Congratulations to our portfolio company Vianautis on the appointment of Adi Hoess as Chief Executive Officer. Dr Hoess has significant biotech leadership experience, and we look forward to the important role he will play in the development and growth of ViaNautis as they progress the polyNaut® platform to create genetic medicines of the future. #AdvancedTherapies #Nanomedicines #DrugDelivery #VC #CEO #Appointment
As ViaNautis advances to its next stages of growth, our Chairman, Steven Altschuler M.D., and the entire team are delighted to announce that Dr Adi Hoess has been appointed as our new Chief Executive Officer: https://lnkd.in/eT3fay-q Dr Hoess, who previously served as CEO of Affimed N.V., brings a wealth of experience and a proven track record of successfully building companies from early pre-clinical stage to late clinical stage. He brings to Vianautis a strong investor network and accomplishments of several IND approvals, partnerships and deals. #ViaNautis #polyNaut #leadership #Biotech #Nanomedicine
-
-
Last week, we enjoyed hosting our Annual Conference and AGM at The Royal Institution in London. The day was filled with insightful panel discussions and fireside chats with leading business and technical experts in the advanced therapies field, including from some of our portfolio companies Araris Biotech AG, SparingVision, Ray Therapeutics, Inc., Trogenix and Vianautis. A big thank you to Philippe Fauchet and Abbas Hussain for moderating the fireside chats and to everyone who participated and attended, including Ascend Advanced Therapies, Entact Bio and Hornet Therapeutics! #4BIO #VC #AdvancedTherapies #GeneTherapy #AGM #Conference #Networking
-
-
Big congratulations to our Advisor Abbas Hussain who has joined Moderna’s Board of Directors. Abbas has more than 35 years of commercial leadership and operating experience in healthcare, having most recently served as CEO at Vifor Pharma. His significant sector expertise is a real asset to 4BIO Capital and we wish him every success in his new appointment at Moderna. Read about Abbas’ appointment in full here - https://lnkd.in/gApv9j3T #4BIO #VC #AdvancedTherapies #GeneTherapy #Appointments